58 results about "Calcium-binding protein" patented technology

The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor / Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least twoof Haemoglobin-beta (Hb-beta), Haemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value reflecting the joint concentrations for said proteins is determined. The value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in the patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in the patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in the patient.

Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10.

A method for measuring the presence of calprotectin (S100A8 / A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The methodcan be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be usedfor measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays(ELISA) has been shown despite of different measurement principles used.

Disclosed is an in vitro method for assessing whether a human patient is free from periodontal disease, has gingivitis, has mild periodontitis or has advanced periodontitis. The method is based on theinsight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of the proteins: Alpha-1-acid glycoprotein (A1AGP) and Pyruvate Kinase (PK),and at least one of the proteins Matrix metalloproteinase-9 (MMP-9) and S100 calcium binding protein A8 (S100A8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient is free from periodontal disease, has gingivitis, has mild periodontitis or has advanced periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with gingivitis, mild or advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal health status in said patient.

Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Profilin and S100 calcium-binding protein A9 (S100A9). Another combination is Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.

The invention discloses a mussel calcium source for pearl cultivation in fresh water and manufacturing and using methods thereof. Each 1000g of mussel calcium source comprises 400-850g for calcium oxide, 100-450g for mussel shell powder, 10-100g for vinegar, 10-100g for compound amino acid, 1-10g for vitamin D and 5-40g for calcium binding protein. The manufacturing method is that: a. the calcium oxide is mashed; b. the mussel shell is mashed and then added with vinegar for acidification; c. the materials from steps a and b are fully mixed with compound amino acid, vitamin D and calcium binding protein to form mussel calcium source for pearl cultivation in fresh water; d. the mixture is packed. The using method is that: a. the calcium source packed in bag is suspended to water with mussel shell for cultivating pearl; b. the times for suspending calcium source are that: one time / 30 days in spring, one time / 20 days in summer and one time / 40 days in autumn; c. the temperature surrounding the calcium source is kept between 15 DEG C and 35 DEG C. The invention has the advantages of scientific prescription, low cost, easy usage and being capable of effectively improving fresh water pearl output and quality.

The invention relates to fusion proteins comprising an amino acid sequence of a fragment H corresponding to a fragment of a calcium binding protein excreted-secreted by adult worms of Fasciola hepatica, followed by an amino acid sequence corresponding to a unrelated protein or fragment of protein, pharmaceutical compositions, vaccines and adjuvants containing the immunogen, to a process for their preparation, another process for the production of antibodies and their use.The present invention relates to the preparation of immunogens by the addition of a peptide sequence.Thus the present invention is useful for producing an immune response, with increases in specific antibody titers in serum against proteins or other antigens and can be applied in particular for the production of specific polyclonal antibodies, immunotherapy and immunoprophylaxis. The addition of the polypeptide to a target antigen, either through the production of recombinant proteins containing the polypeptide or by addition or fusion of this polypeptide with the target antigen, induces a significant increase in the immunogenicity of these molecules, amplifying the immune response elicited by injection of this molecule in a subject susceptible to produce antibodies.